2023年ESMO大会将于10月20日-24日在西班牙马德里举行，大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展，为临床实践、多学科讨论等提供广阔、卓越的学术平台。
近日，ESMO官网公布了除LBA外的摘要标题。本期小编整理本次批露的头颈肿瘤领域重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
Mini oral session - 头颈部肿瘤
专场时间：2023年10月21日16:15-17:45（本文时间均为北京时间）
专场地点：Málaga Auditorium - Hall 10
本专场有2个LBA摘要待确认（TBC）
本场LBA：
摘要号：LBA46
SAKK 11/16，一项评估基于细胞微囊封装的免疫治疗首创新药（First-in-Class）MVX-ONCO-1对在系统治疗≥1线后进展的复发/转移性头颈部鳞状细胞癌（RMHNSCC）患者（pts）总生存（OS）的IIa期试验
LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & Neck Squamous Cell Carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy.
讲者：Nicolas Mach (Geneva, Switzerland)
摘要号：LBA47
一项评估tipifarnib用于mHRAS突变的复发或转移（R/M）头颈部鳞状细胞癌（HNSCC）的II期临床试验（AIM-HN研究） LBA47 - A phase 2 study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
讲者：Alan L. Ho (New York, United States of America)
摘要号：855MO
对接受挽救性手术的头颈部鳞状细胞癌（HNSCC）患者的辅助免疫治疗：评估纳武利尤单抗疗效和毒性的II期临床试验（ADJORL1）
Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): phase 2 trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1).
讲者：Joanne Guerlain (Villejuif, France)
以下非LBA，为普通MO
摘要号：856MO
一项随机II期研究：同步放化疗vs序贯放化疗对使用帕博利珠单抗的局部晚期头颈癌（LA-HNSCC）患者的4年结果和肿瘤免疫微环境分析
A Randomized Phase II Study of Concurrent vs. Sequential Pembrolizumab with Chemoradiation (CRT) in Locally Advanced Head and Neck Cancer (LA-HNSCC): 4-year results and tumor-immune microenvironment analysis.
讲者：Dan P. Zandberg (Baltimore, United States of America)
摘要号：857MO
MACH-EGFR：局部晚期（LA）头颈部鳞状细胞癌（SCCHN）患者抗EGFR单克隆抗体（Ab）的个人患者数据（IPD）荟萃分析
MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)
讲者：Pierre Blanchard (Villejuif, Cedex, France)
摘要号：858MO
局部晚期（LA）头颈部鳞状细胞癌（SCCHN）治疗后，用血浆循环肿瘤DNA（ctDNA）诊断的微小残留病灶 (MRD) ，预测疾病复发和生存
After treatment for locally advanced (LA) head and neck squamous cell carcinoma (SCCHN), minimal residual disease (MRD) diagnosed through plasma tumor agnostic circulating tumor DNA (ctDNA) detection can predict disease recurrence and survival rate.
讲者：Natasha Honoré (Woluwe-Saint-Lambert, Belgium)
摘要号：859MO
戈沙妥珠单抗（SG）治疗复发/难治性（R/R）晚期头颈部鳞状细胞癌（HNSCC）患者（pts）：II期TROPiCS-03篮子试验结果
Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial
讲者：Loren Michel (New York, United States of America)
摘要号：860MO
MRG003，一种治疗复发/转移性鼻咽癌的新型EGFR靶向抗体-药物偶联物（ADC）
MRG003, a novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic Nasopharyngeal Carcinoma
讲者：韩非(中国,广州)
Proffered Paper session - 头颈部肿瘤
专场时间：2023年10月23日 14:30-16:00
专场地点：Burgos Auditorium - Hall 3
专场主席：Paolo Bossi (Rozzano, Italy) Silke Tribius (Hamburg, Germany)
本专场有3个LBA摘要TBC
摘要号：853O
在使用立体定向消融放疗（SABR）治疗有1-3个寡转移灶的头颈癌（HNSCC）患者中省略一线化疗，GORTEC 2014-04 “OMET”随机II期试验
OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial
讲者：Juliette Thariat (Caen, Cedex, France)
摘要号：854O
INTERLINK-1: III期研究-对铂类化疗后疾病进展及之前接受过免疫检查点抑制剂治疗的复发/转移头颈鳞状细胞癌(R/M HNSCC) 患者使用西妥昔单抗(CTX)±monalizumab (M)
A Pooled Analysis of INTERLINK-1: Phase 3 study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
讲者：Jérome Fayette (Lyon, France)
摘要号：857O
局部晚期（LA）头颈部鳞状细胞癌（HNSCC）患者抗EGFR单克隆抗体（Ab）使用的个体患者数据（IPD）荟萃分析
MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)
讲者：Pierre Blanchard (Villejuif, Cedex, France)
摘要号：858O
局部晚期（LA）头颈部鳞状细胞癌（HNSCC）治疗后通过血浆肿瘤不可知循环肿瘤DNA（ctDNA）检测诊断的微小残留病灶（MRD）预测疾病复发和生存
Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival
讲者：Natasha Honoré (Brussels, Belgium)
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar
苏公网安备32059002004080号
